Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003519 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women With Breast Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,778
- Enrollment target
NCT00003519: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00003519 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 2,778 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (260% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003519, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,778 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating women with breast cancer who have undergone surgery to remove the tumor.
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,778 participants |
| Start Date | 1998-08-20 |
| Phase | Phase 3 |
What the finished NCT00003519 record still lists
NCT00003519 is an interventional study that assigns participants to a tested intervention. Its 2,778 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (260% higher).
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00003519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003519 about?
NCT00003519 is a clinical study titled "Combination Chemotherapy in Treating Women With Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase I...
What is the current status of trial NCT00003519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,778 participants. The study started on 1998-08-20.
What interventions are being tested in trial NCT00003519?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003519?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003519's enrollment target sits among peer trials
2,778 82nd of 2000 higher than 1,919 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI